All topics

Community and awareness

Advocacy, fundraisers, awareness, patient stories, community events, and public-facing IBD news.

Page 6 of 10 · 476 articles

Johnson & Johnson (NYSE:JNJ) Presents Promising TREMFYA Study Results At Digestive Disease Week 2025
finance.yahoo.com

Johnson & Johnson (NYSE:JNJ) Presents Promising TREMFYA Study Results At Digestive Disease Week 2025

TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...

Read Summary